Gepirone, a new depression drug by Fabre-Kramer Pharmaceuticals, did not meet the FDAs efficacy standards. The new drug application for gepirone has now received “not approvable” review three times.
-
But that’s okay. Just keep trying and it will get approved. Even if there are 187 failed trials, if trial #188 and #189 are positive by chance, that’s all the FDA needs to say this drug is safe and effective for depression.
